Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors to treat diseases driven by the overproduction of palmitate. Its lead drug candidate, denifanstat, is an oral, once-daily selective FASN inhibitor in development for metabolic dysfunction-associated steatohepatitis (MASH), acne, and select forms of cancer. A second FASN inhibitor, TVB-3567, is in development for acne. The company is developing a combination of denifanstat and resmetirom for cirrhotic MASH patients. In China, license partner Ascletis BioScience Co. Ltd. is developing denifanstat for moderate to severe acne. Sagimet also employs a biomarker strategy using non-invasive tests to identify patients likely to respond to its therapies.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage sagimet.com
Sector Healthcare IR page ir.sagimet.com/news-releases
Tags
fatty acid synthase inhibitors, metabolic dysfunction-associated steatohepatitis, acne, lipid metabolism, fibrosis, small molecule therapeutics, precision medicine, biomarkers, denifanstat, TVB-3567, TVB-3664, resmetirom, Rezdiffra, ASC40, Ascletis BioScience Co. Ltd., Ascletis Pharma Inc., FASCINATE-2, AURORA
Press page —

Metrics

Valuation  
Market cap $ 615.913M
Market cap (USD) $ 615.913M
P/E -8.23
PEG —
P/BV 2.54
P/S 307.96
P/OCF -14.11
P/FCF -13.49
Dividend yield —
Turnover / mcap —
Returns  
ROE -38.2%
ROI -45.8%
ROIC -38.3%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 53
Quality score -75.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue — — 2M 0 0
Net profit -51.038M -45.567M -27.876M -30.499M -24.442M
Free cash flow -45.65M -42.435M -23.766M -24.49M -21.71M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 5.92 4.5 5.42 — —
Price performance 12m 0.32 -0.17 — — —

Filed figures

Figure Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 211,000 65,000 78,000 78,000
Cash and deposits (USD) 56.7M 158,000 75.1M 75.8M 35M
Right-of-use assets (USD) — 212,000 73,000 77,000 78,000
Cash flow detail
Operating cash flow (USD) — -24.5M -23.8M -42.4M -45.7M
Change in payables (cash effect) (USD) — 2.92M 120,000 -907,000 929,000
Share-based compensation (USD) — 1.88M 4.99M 5.29M 6.45M
Income detail
Research and development expense (USD) — 24.9M 19.8M 38.4M 39.1M
Total comprehensive income (USD) — -30.6M -27.8M -45.4M -51.1M
Comprehensive income to owners (USD) — -30.6M -27.8M -45.4M -51.1M
Reported Aug 21, 2023 Mar 25, 2024 Mar 25, 2024 Mar 12, 2025 Mar 11, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

• Registrational U.S. AURORA Phase 3 clinical trial underway for denifanstat in moderate to severe acne, with topline data anticipated in the second half of 2027

• Positive denifanstat Phase 3 clinical trial results in China from license partner Ascletis, and continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks in the open-label extension clinical trial, presented at EADV 2026 and Fall Clinical Dermatology 2026

• Completed underwritten offering of Series A Common Stock and pre-funded warrants in October, with gross proceeds of $115 million

• Pro forma cash and investments balance of approximately $356 million as of September 30, expected to fund current operations through mid-2029 including through readout of data from the denifanstat AURORA Phase 3 clinical trial in moderate to severe acne and potential NDA submission

FOSTER CITY, Calif., November 12, 2026 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc.

10/29/2026 at 7:00 AM EDT

PDF Version

FOSTER CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis regulator, for acne, today announced that management will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference on Monday, November 9, 2026, in Boston, MA with a fireside chat at 10:30am ET (link here).

Inducement Grant

In connection with the hiring of two employees, the Compensation Committee of Sagimet’s Board of Directors approved that an inducement grant of 63,600 stock options in aggregate to purchase shares of the Company’s Series A common stock be granted on October 28, 2026 to the newly hired employees.

The option awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensation and were granted as an inducement material to the acceptance of employment with Sagimet.

The options have an exercise price equal to the closing price of Sagimet’s Series A common stock as reported by the Nasdaq Global Market on October 28, 2026. The options have a ten-year term and vest over four years, with 25% of the number of shares underlying each stock option vesting on the one-year anniversary of the applicable vesting commencement date (based on the employee’s employment commencement date) and the remaining shares vesting monthly over 36 months thereafter, subject to each individual’s continued service with Sagimet through the applicable vesting dates.

About Sagimet Biosciences

Sagimet is a clinical-stage biopharmaceutical company advancing a portfolio of novel fatty acid synthase (FASN) inhibitors. FASN is a key regulator of the de novo lipogenesis pathway, which is overactive in acne and can cause elevated sebum and inflammation. FASN is also implicated in other diseases, including MASH and certain FASN-dependent tumor types. Denifanstat, Sagimet’s lead drug candidate, is an oral, once-daily FASN inhibitor currently being evaluated in a U.S. Phase 3 registrational clinical trial for moderate to severe acne. For more information, visit www.sagimet.com.

Investor Contact: Joyce Allaire LifeSci Advisors [email protected]

Media Contact: Maggie Whitney LifeSci Communications [email protected]

Primary Logo

Site Map

Contact Us

Business Development: [email protected]

Investors: [email protected]

Media: [email protected]

© 2026 Sagimet Biosciences Inc.. All Rights Reserved.

Main navigation

Close line1 Close line2

On October 22, 2026, Sagimet Biosciences Inc. (the “Company”) updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.

Prompts

Sagimet Biosciences Inc. (ticker SGMT), listed in United States.

Company History

Date Change Detail
Jan 5, 2021 Renamed 3-V Biosciences, Inc. → SAGIMET BIOSCIENCES INC.

ETFs Holding Sagimet Biosciences Inc.

ETF Weight in ETF Shares Market value As of
BMED 0.13% 1,875 $ 18.994K Nov 16, 2026
RESM 0.01% 68 $ 525.64 Jun 30, 2026
DFAS 0.01% 260,924 $ 2.852M Nov 12, 2026
DFSU 0.00% 7,194 $ 78.63K Nov 12, 2026
DFUS 0.00% 32,555 $ 355.826K Nov 12, 2026
DCOR 0.00% 61,135 $ 668.206K Nov 12, 2026
DFAU 0.00% 12,351 $ 134.996K Nov 12, 2026
DFAC 0.00% 77,731 $ 849.6K Nov 12, 2026
DXUV 0.00% 2,377 $ 25.981K Nov 12, 2026